

E.A.N.O. Foreign Correspondent Guidelines

Guidelines for E.A.N.O. "Foreign correspondents" for the EANO website.

We would envisage a letter from each foreign correspondent

- 2 articles a year
- English (but needn't be perfect)

The letter hopefully should be informative, but informal. People in other European countries may not know about neuro-oncology in your country and might find the things that are going on relevant. The letter could be about things going on in your country, either with the

- Health system,
- Cancer in general
- Neuro-oncology in particular.

This can be in the form of

- Politics
- Policy
- Education
- Research
- Clinical topics
- Meetings coming up
- Nursing issues
 - It can be:
 - information
 - requests for advice
 - involvement of other countries

Basically, the letter should be informative, educational and mention some new developments or potential. Authors can stamp their own personal style on it.

Robin Grant & Khê Hoang-Xuan
E.A.N.O. Board Members
Email: office@eano.eu
www.eano.eu

Letter from the UK. (Example Foreign Correspondents EANO)

PICTURE OR COUNTRYFLAG CAN BE ADDED (BY PREFERENCE)

Written by

Cancer continues to be a Government priority with the announcement of a major network of Experimental Cancer Medicine Centres (ECMC) across the UK with a funding boost of £35 million. Neuro-Oncology services are beginning to obtain a higher profile and waiting times are coming down across the UK.

The Scottish Adult Neuro-Oncology Network will receive support in 2007, as a National Managed Clinical Network. Members are working on a national dataset, clinical dataset, protocols and pathways, as well as research portfolio and education.

NICE (National Institute for Health and Clinical Excellence) have produced service guidance for improving outcomes for people with brain and other CNS tumours. See guidance (<http://www.nice.org.uk/guidance/csgbraincns/guidance/pdf/English>)

In England and Wales, concomitant Temozolomide has been recommended by NICE for newly diagnosed GBM in patients with a World Health Organization (WHO) performance status of 0 or 1. Carmustine implants were not recommended.

Meanwhile, in Scotland, the Scottish Medicines Consortium accepted Gliadel as adjunct to surgery in malignant glioma but Temozolomide was given a restricted licence only for patients who have had a partial or complete resection, who are WHO grade 0-1.

<http://www.scottishmedicines.org.uk/press/detail.asp?id=1159>

British Neuro-Oncology Society Meeting this year will be held in Portsmouth - 13th to 15th June, 2007. hosted by Prof. Geoff Pilkington. For more information contact the BNOS website

<http://www.bnos.org.uk/>

Junior doctors training is undergoing a major overhaul! Any prospective doctors considering coming to the UK should see the MMC website. <http://www.mmc.nhs.uk/pages/home>